Clinical and Functional Consequences of C-Terminal Variants in MCT8: A Case Series
Open Access
- 3 November 2020
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (2) , 539-553
Abstract
Context Genetic variants in SLC16A2, encoding the thyroid hormone transporter MCT8, can cause intellectual and motor disability and abnormal serum thyroid function tests, known as MCT8 deficiency. The C-terminal domain of MCT8 is poorly conserved, which complicates prediction of the deleteriousness of variants in this region. We studied the functional consequences of 5 novel variants within this domain and their relation to the clinical phenotypes. Methods We enrolled male subjects with intellectual disability in whom genetic variants were identified in exon 6 of SLC16A2. The impact of identified variants was evaluated in transiently transfected cell lines and patient-derived fibroblasts. Results Seven individuals from 5 families harbored potentially deleterious variants affecting the C-terminal domain of MCT8. Two boys with clinical features considered atypical for MCT8 deficiency had a missense variant [c.1724A>G;p.(His575Arg) or c.1796A>G;p.(Asn599Ser)] that did not affect MCT8 function in transfected cells or patient-derived fibroblasts, challenging a causal relationship. Two brothers with classical MCT8 deficiency had a truncating c.1695delT;p.(Val566*) variant that completely inactivated MCT8 in vitro. The 3 other boys had relatively less-severe clinical features and harbored frameshift variants that elongate the MCT8 protein [c.1805delT;p.(Leu602HisfsTer680) and c.del1826-1835;p.(Pro609GlnfsTer676)] and retained ~50% residual activity. Additional truncating variants within transmembrane domain 12 were fully inactivating, whereas those within the intracellular C-terminal tail were tolerated. Conclusions Variants affecting the intracellular C-terminal tail of MCT8 are likely benign unless they cause frameshifts that elongate the MCT8 protein. These findings provide clinical guidance in the assessment of the pathogenicity of variants within the C-terminal domain of MCT8.Keywords
Funding Information
- Netherlands Organisation for Health Research and Development (113303005)
- Sherman Foundation
This publication has 38 references indexed in Scilit:
- Essential Molecular Determinants for Thyroid Hormone Transport and First Structural Implications for Monocarboxylate Transporter 8Journal of Biological Chemistry, 2010
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- Evidence for a Homodimeric Structure of Human Monocarboxylate Transporter 8Endocrinology, 2009
- Surface translocation and tri-iodothyronine uptake of mutant MCT8 proteins are cell type-dependentJournal of Molecular Endocrinology, 2009
- Novel pathogenic mechanism suggested by ex vivo analysis of MCT8 (SLC16A2) mutationsHuman Mutation, 2008
- Decreased cellular uptake and metabolism in Allan-Herndon-Dudley syndrome (AHDS) due to a novel mutation in the MCT8 thyroid hormone transporterJournal of Medical Genetics, 2005
- Allan-Herndon-Dudley Syndrome and the Monocarboxylate Transporter 8 (MCT8) GeneThe American Journal of Human Genetics, 2005
- A Novel Syndrome Combining Thyroid and Neurological Abnormalities Is Associated with Mutations in a Monocarboxylate Transporter GeneThe American Journal of Human Genetics, 2004
- Identification of Monocarboxylate Transporter 8 as a Specific Thyroid Hormone TransporterJournal of Biological Chemistry, 2003
- Organization of Signaling Complexes by PDZ-Domain Scaffold ProteinsAccounts of Chemical Research, 2003